KUALA LUMPUR, June 12 (Bernama) -- US based Neuralstem Inc has been awarded US$150,000 (RM598,366.73) for Phase I Small Business Innovation Research (SBIR) contract by the Department of Defense (DoD) to support effort to find cure for brain injury.
This research is intended to culminate in the filing of an IND application to conduct clinical trials in Traumatic Brain Injury (TBI).
Neuralstem is a biopharmaceutical company developing novel treatments for nervous system diseases.
The company in a statement said the award will support the Neuralstem's ongoing efforts to develop its NSI-566 human neural stem cell line as a candidate therapeutic for severe TBI.
President and Chief Executive Officer of Neuralstem, Rich Daly said: "Severe TBI represents a significant unmet medical need and we are excited to continue our preclinical studies to establish the therapeutic potential of neural stem cells in this indication."
Approximately 3 to 5 million people in the United States have a disability resulting from TBI, with rehabilitative therapy currently serving as the primary treatment method.
The research supported by the SBIR contract will facilitate the progress of Neuralstem's ongoing collaboration with the research group of Dr Ross Bullock, Department of Neurological Surgery and Director, Clinical Neurotrauma at the Miami Project to Cure Paralysis.
--BERNAMA
No comments:
Post a Comment